Masonic Cancer Center, University of Minnesota
Trial Pipeline
LEgal Guidance and AdvocaCY for CAREgivers (LEGACY CARE): A Pilot Clinical Trial for Caregivers of Persons With Colorectal Cancer
NCT07153016
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
NCT06792825
UNTOLD Ovarian Cancer Unmet Needs Survey
NCT07070726
Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
NCT07008638
American Indian Smokefree Native RCT
NCT06544811
Trial of Cell Based Therapy for DMD
NCT06692426
Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through Exercise
NCT05025774
Adenovirus (RGDCRAdCOX2F)
NCT06693986
MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma
NCT06377540
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
NCT06594445
Allo HSCT for High Risk Hemoglobinopathies
NCT06872333
Effects of Relighting on Smoke Toxicant Deliveries and Subjective Smoking Measures
NCT06295757
Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
NCT06342986
MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
NCT06412497
Evaluation of Early Identification of Cognitive Side Effects of Immunotherapy
NCT06414278
Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy
NCT06411795
Study of PAT in Patients With Solid Tumor Cancers
NCT05338658
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
NCT05735717
Allo HSCT Using RIC and PTCy for Hematological Diseases
NCT05805605
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
NCT04105270
Role of Acetaldehyde in the Development of Oral Cancer
NCT05973656
Observational Study of Exposure to Environmental Toxicants Among Firefighters
NCT05643014
Adrenoleukodystrophy National Registry Study
NCT03789721
Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
NCT03579875
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
NCT03314974
Auto Stem Cell Transplant for Lymphoma Patients
NCT03125642
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
NCT01962636
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
NCT02605421
Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation
NCT02161783
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
NCT01666080
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
NCT01451502
Assessing the Time Demands of Cancer
NCT05708703
Increasing HPV Vaccination in Pediatric, Adolescent, and Young Adult (PAYA) Cancer Survivors
NCT05665543
Evaluation of Intravenous Laronidase Pharmacokinetics Before and After Hematopoietic Cell Transplantation in Patients With Mucopolysaccharidosis Type IH.
NCT05634512
NF-1, Nutraceutical Intervention
NCT05363267
Biomarkers of Exposure and Effect in Standardized Research E-cigarette (SREC) Users
NCT04003805
Nornicotine in Smokeless Tobacco as a Precursor for Carcinogen Exposure
NCT03998735
Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin Post Axi-Cel
NCT04514029
CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone
NCT03934840
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
NCT03674411
MT2017-45: CAR-T Cell Therapy for Heme Malignancies
NCT03642626
MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis
NCT02171104
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
NCT01652092
Feasibility Study - Filter Ventilation
NCT04514471
EMR Chemotoxicity Risk Calculator To Decrease Chemotherapy Toxicity
NCT05809557
HCW9218 in Select Advanced Solid Tumors
NCT05322408
Impact of Low Nicotine Cigarette Messaging on Perceptions and Cigarette Choices
NCT04740008
FT516 and IL2 With Enoblituzumab for Ovarian Cancer
NCT04630769
Clinical Trial of Two Study Drinks in Detoxification of Environmental Toxicants and Carcinogens
NCT03978117
Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS
NCT04055844
Radiation and Combination Immunotherapy for Melanoma
NCT03850691
BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy
NCT03294304
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL
NCT03019666
HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma
NCT02370160
Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia
NCT02162420
NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases
NCT01370213
Selecting a Favorable KIR Donor in Unrelated HCT for AML
NCT01288222
Metabolism of NNK Among African Americans
NCT01158456
Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer
NCT01105650
Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer
NCT01009437
IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread
NCT01099631
Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs
NCT01033552
Iron Overload in Patients Undergoing Donor Stem Cell Transplant
NCT00888316
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
NCT00703638
Intrathecal Enzyme Replacement for Hurler Syndrome
NCT00638547
T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer
NCT00602693
CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer
NCT00610740
Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia
NCT00274846
Stem Cell Transplant for Hemoglobinopathy
NCT00176852
Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia
NCT00258427
Stem Cell Transplantation for Hurler
NCT00176917
Stem Cell Transplant for Inborn Errors of Metabolism
NCT00176904
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 48 |
| Phase 2 | 28 |
What the Pipeline for Masonic Cancer Center, University of Minnesota Shows
According to the ClinicalTrials.gov registry, Masonic Cancer Center, University of Minnesota is linked to 154 US clinical trials across every stage of research activity. Of those, 113 studies are currently recruiting — about 73% of the sponsor's indexed portfolio — and 29 are already marked complete, representing roughly 19% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Masonic Cancer Center, University of Minnesota reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 76 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Masonic Cancer Center, University of Minnesota is Acute Myeloid Leukemia with 7 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.